A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma
详细信息 查看全文
- 作者：Oscar Arrieta (1)
Diego López-Macías (1)
Víctor-Osvaldo Mendoza-García (1)
Ludwing Bacon-Fonseca (1)
Wendy Mu?oz-Monta?o (1)
Eleazar-Omar Macedo-Pérez (1)
Saé Mu?iz-Hernández (1)
Monika Blake-Cerda (1)
José-Francisco Corona-Cruz (1) - 关键词：Mesothelioma ; Prolonged infusion ; Gemcitabine ; Cisplatin
- 刊名：Cancer Chemotherapy and Pharmacology
- 出版年：2014
- 出版时间：May 2014
- 年：2014
- 卷：73
- 期：5
- 页码：975-982
- 全文大小：
- 参考文献：1. Selikoff IJ, Hammond EC, Seidman H (1980) Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 46(12):2736-740 CrossRef
2. Tsao AS, Wistuba I, Roth JA et al (2009) Malig Pleur Mesothelioma J Clin Oncol 27(12):2081-090. doi:10.1200/JCO.2008.19.8523 CrossRef
3. Delgermaa V, Takahashi K, Park EK et al (2011) Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89(10):716-24. doi:10.2471/BLT.11.086678 724A-24C CrossRef
4. Aguilar-Madrid G, Robles-Pérez E, Juárez-Pérez CA et al (2010) Case-control study of pleural mesothelioma in workers with social security in Mexico. Am J Ind Med 53(3):241-51
5. García-López MP, Barrera-Rodríguez R (2000) Malignant mesothelioma: clinical and radiological description of 45 cases with and without asbestos exposure. Salud Publica Mex 42(6):511-19 CrossRef
6. Park EK, Takahashi K, Hoshuyama T et al (2011) Global magnitude of reported and unreported mesothelioma. Environ Health Perspect 119(4):514-18. doi:10.1289/ehp.1002845 CrossRef
7. NCCN Guidelines for Treatment of Malignat Pleural Mesothelioma (2013) IOP National Comprehensive Cancer Network Web. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed 23 Dec 2013
8. Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636-644 CrossRef
9. van Meerbeeck JP, Gaafaar R, Manegold C et al (2005) Randomized phase III Study of Cisplatin With or Without Ralitrexed in Patients with Malignant Pleural Mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23(28):2636-644
10. Kelly RJ, Sharon E, Hassan R (2011) Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer 73(3):256-63. doi:10.1016/j.lungcan.2011.04.014 CrossRef
11. Nowak AK, Byrne MJ, Williamson R et al (2002) A multicenter phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87(5):491-96 CrossRef
12. Arrieta ó, Medina LA, Estrada-Lobato E et al (2012) First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer 106(6):1027-032. doi:10.1038/bjc.2012.44 CrossRef
13. Ralli M, Tourkantonis I, Makrilia N et al (2009) Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res 29(8):3441-444
14. S?rensen JB, Frank H, Palshof T (2008) Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleuralmesothelioma. Br J Cancer 99(1):44-0. doi:10.1038/sj.bjc.6604421 CrossRef
15. Boons CC, VAN Tulder MW, Burgers JA et al (2013) The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review. Anticancer 33(9):3553-561
16. Grossi F, Genova C, Gaitan ND et al (2013) Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy. Lung Cancer 81(2):236-40. doi:10.1016/j.lungcan.2013.03.021 CrossRef
17. Woods B, Paracha N, Scott DA et al (2012) Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. Lung Cancer 75(2):261-67. doi:10.1016/j.lungcan.2011.07.011 CrossRef
18. Zwitter M, Kovac V, Smrdel U et al (2009) Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. J Thorac Oncol 4(9):1148-155. doi:10.1097/JTO.0b013e3181ae280f CrossRef
19. Sezer O, Eucker J, Jakob C et al (2001) Achievement of complete remission in refractory Hodgkin’s disease with prolonged infusion of gemcitabine. Invest New Drugs 19(1):101-04 CrossRef
20. Brand R, Capadano M, Tempero M (2007) A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15(4):331-41 CrossRef
21. Akrivakis K, Schmid P, Flath B et al (1999) Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs 10(6):525-31 CrossRef
22. Cattel L, Airoldi M, Delprino L et al (2006) Pharmacokinetic evaluation of gemcitabine and 2-2-difluorodeoxycytidine-5-triphosphate after prolonged infusion in patients affected by different solid tumors. Ann Oncol 17(Suppl 5):v142–v147 CrossRef
23. Maurel J, Zorrilla M, Puertolas T et al (2001) Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs 12(9):713-17 CrossRef
24. Anderson H, Thatcher N, Walling J et al (1996) A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer 74(3):460-62 CrossRef
25. Pollera CF, Ceribelli A, Crecco M et al (1997) Prolonged infusion gemcitabine: a clinical phase I study at low-(300?mg/m2) and high-dose (875?mg/m2) levels. Invest New Drugs 15(2):115-21 CrossRef
26. Touroutoglou N, Gravel D, Raber MN et al (1998) Clinical results of a pharmacodynamically based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9(9):1003-008 CrossRef
27. Abbruzzese JL, Grunewald R, Weeks EA et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9(3):491-98
28. Plunkett W, Huang P, Xu YZ et al (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22(4 Suppl 11):3-0
29. Edwards JG, Abrams KR, Leverment JN et al (2000) Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55(9):731-35 CrossRef
30. Fennell DA, Parmar A, Shamash J et al (2005) Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 23(1):184-89 CrossRef
31. Arrieta ó, Nú?ez-Valencia C, Reynoso-Erazo L et al (2012) Health-related quality of life in patients with lung cancer: validation of the Mexican–Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer 77(1):205-11. doi:10.1016/j.lungcan.2012.02.005 CrossRef
32. Schouwink JH, Kool LS, Rutgers EJ et al (2003) The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. Ann Thorac Surg 75(6):1715-718 CrossRef
33. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson BW et al (1999) Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17(1):25-0
34. van Haarst JM, Baas P, Manegold Ch et al (2002) Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86(3):342-45 CrossRef
35. Kalmadi SR, Rankin C, Kraut MJ et al (2008) Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 60(2):259-63 CrossRef
36. Castagneto B, Zai S, Dongiovanni D et al (2005) Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 28(3):223-26 CrossRef
37. Favaretto AG, Aversa SM, Paccagnella A et al (2003) Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 97(11):2791-797 CrossRef
38. Ceribelli A, Gridelli C, De Marinis F et al (2003) Prolonged gemcitabine infusion in advanced non-small cell lung cancer carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 98(2):337-43 CrossRef
39. de Perrot M, Feld R, Cho BC et al (2009) Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27(9):1413-418. doi:10.1200/JCO.2008.17.5604 CrossRef
40. Lee CW, Murray N, Anderson H et al (2009) Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 64(3):308-13. doi:10.1016/j.lungcan.2008.09.008 CrossRef
41. Kovac V, Zwitter M, Rajer M et al (2012) A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma. Anticancer Drugs 23(2):230-38. doi:10.1097/CAD.0b013e32834d7a1c CrossRef
42. Rea F, Marulli G, Bortolotti L et al (2007) Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer 57(1):89-5 CrossRef
43. Bottomley A, Coens C, Efficace F et al (2007) Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 25(36):5770-776 CrossRef
44. Flores RM, Pass HI, Seshan VE et al (2008) Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135(3):620-26. doi:10.1016/j.jtcvs.2007.10.054 CrossRef
45. Treasure T, Lang-Lazdunski L, Waller D et al (2011) Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural?mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12(8):763-72. doi:10.1016/S1470-2045(11)70149-8 CrossRef - 作者单位：Oscar Arrieta (1)
Diego López-Macías (1)
Víctor-Osvaldo Mendoza-García (1)
Ludwing Bacon-Fonseca (1)
Wendy Mu?oz-Monta?o (1)
Eleazar-Omar Macedo-Pérez (1)
Saé Mu?iz-Hernández (1)
Monika Blake-Cerda (1)
José-Francisco Corona-Cruz (1)
1. Thoracic Oncology Unit, Experimental Oncology Laboratory, Instituto Nacional de Cancerología (INCan), San Fernando # 22, Col. Sección XVI, Tlalpan, C.P. 14080, Mexico, D.F., Mexico - ISSN：1432-0843
文摘
Purpose Low-dose, prolonged infusion of gemcitabine has effects similar to standard doses in several cancers. We evaluated the toxicity and efficacy of low-dose gemcitabine in prolonged infusion plus cisplatin in patients with advanced pleural mesothelioma. Methods Patients with mesothelioma received gemcitabine (250?mg/m2) in a 6-h infusion plus cisplatin (35?mg/m2) on days 1 and 8 every three weeks. We used the modified response evaluation criteria in solid tumours. This study is registered in clinical trials (NCT01869023). Results We included 39 patients; 82.1?% were low risk according to the European Organisation for Research and Treatment of Cancer prognostic group. Partial response was observed in 53.8?% (21/39), stable disease in 33.3?% (13/39) and progression in 12.8?% (5/39). The median progression-free survival was 6.9?months (95?% CI 3.2-0.6?months), and the associated factors were the EORTC risk and histology. The median overall survival was 20.7?months (95?% CI 10.7-0.8?months). The functional, physical and emotional roles and dyspnoea, insomnia and pain symptom scales improved. The most commonly graded 3/4 side effects were neutropenia (24.4?%), lymphopenia (14.6?%), thrombocytopenia (14.7?%) and anaemia (12.2?%). Conclusions Low-dose, prolonged gemcitabine infusion plus cisplatin has acceptable toxicity and high efficacy with improved quality of life, representing an affordable regimen for the low-income population.